A Double-blind, Randomised, Placebo-controlled Study of the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Oral Doses of V81444 in Healthy Male Volunteers.
Phase of Trial: Phase I
Latest Information Update: 26 Sep 2013
At a glance
- Drugs CPI 444 (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- Sponsors Vernalis
- 09 Jul 2012 Additional lead trial investigator (Steve Warrington) identified, official title amended and actual patient number is 49 as reported by ClinicalTrials.gov.
- 09 Jul 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01634568).
- 02 May 2012 Results from this trial were presented, according to a Vernalis media release.